Worth reading
62In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
50
¥100 million (FY2027 sales target)Wording
Avoiding a definitive answer
How definitive the wording is.Items stated in the management plan
Partially revisedNet SalesNot disclosed → ¥5 billion
Operating profitNot disclosed → ¥500 million
Operating profit marginNot disclosed → 10％
Only the target level is shown because the current level for comparison was not provided.Investment amount by sectorField Investment in expanding GCTP-compliant facilities / Amount Not disclosed
Key initiatives
01Evolve into an active, specialized division structure by business area
02Double Jack revenue
03Develop the market for Jasmine
04Build a stable earnings base through phase advancement
05Deliver unique value as an innovation partner
06Create synergies with Teijin
07Accelerate European expansion and establish manufacturing facilities
08Enter new industries
09Further strengthen the platform
10Develop new exit strategies
11Realize new technologies
12Upgrade collaboration and production capabilities
Plan assumptionsMaintain recovery at Q4 FY2026 levels, Cost control at a 10% profit margin
Segment targetSegment Regenerative medicine products business / Sales Target ¥3.5 billion / Profit Target Not disclosed / Timing FY2027, Segment Regenerative medicine contract services business / Sales Target ¥1 billion / Profit Target Not disclosed / Timing FY2027, Segment Labsite business / Sales Target ¥500 million / Profit Target Not disclosed / Timing FY2027
Non-financial targetsIndicator Jack cases / Target value 350 cases/year / Timing Fiscal 2026, Indicator Jack cases / Target value 600 cases/year / Timing FY2027, Indicator Jasmine cases / Target value 50 cases/year / Timing Fiscal 2026, Indicator Jasmine cases / Target value 100 cases/year / Timing FY2027, Indicator Establishing a framework for commercial manufacturing (CMO) / Target value 3 items / Timing FY2027, Indicator Regular Labsite customers / Target value 8 companies / Timing FY2025, Indicator Regular Labsite customers / Target value 11 companies / Timing Fiscal 2026, Indicator Completion of German subsidiary establishment / Target value First half of the fiscal year ending March 2027 / Timing Fiscal year ending March 2027, Indicator Launch of intestinal epithelial model / Target value Second half of the fiscal year ending March 2027 / Timing Fiscal year ending March 2027
Size of the Target MarketRegion EU / Market Size ¥16 billion / CAGR 3.8％ / Source MARKETSANDMARKETS「IN VITRO TOXICITY TESTING MARKET GLOBAL FORECAST TO 2025」, Region United States / Market Size ¥17.4 billion / CAGR 7.1％ / Source MARKETSANDMARKETS「IN VITRO TOXICITY TESTING MARKET GLOBAL FORECAST TO 2025」, Region India / Market Size ¥4.7 billion / CAGR 12.5％ / Source MARKETSANDMARKETS「IN VITRO TOXICITY TESTING MARKET GLOBAL FORECAST TO 2025」, Market Global non-genetically modified cell therapy / Market Size 875 (total pipeline) / Growth rate Up 6% from December 2022 / Source American Society of Gene & Cell Therapy / Citeline「Gene, Cell, & RNA Therapy Landscape」
Risks identified by the company
Changes in the market environment (lower sales due to market size and competitive conditions, and contract revisions resulting from policy changes by contracting parties)
Stable product supply and procurement (difficulty procuring hard-to-substitute raw materials and manufacturing stoppages)
Changes in laws and regulations (unexpected legal amendments and changes in healthcare administration)
Loss of specialized personnel (employee turnover amid intensifying competition and the spread of diverse work styles)
Large-scale disasters (operational shutdowns due to concentration of facilities and surgical delays caused by pressure on medical services)
Information leaks (leakage of confidential information due to cyberattacks or employee negligence)
Reason for revision or withdrawal
Allo-JaCE03 was delayed by 1 year due to the extension of the implementation period for establishing a stable manufacturing process, The launch timing for the intestinal model was reset to the second half of the fiscal year ending March 2027, with priority given to establishing an appropriate quality evaluation system
| Item | Details |
|---|---|
| Plan name | Business Plan and Growth Potential |
| Plan period | FY2025-FY2027 |
| Progress against the plan | Partially revised |
| Sales Target | Not disclosed → ¥5 billion |
| Operating profit target | Not disclosed → ¥500 million |
| Operating profit margin target | Not disclosed → 10％ |
| Investment amount by sector | Field Investment in expanding GCTP-compliant facilities / Amount Not disclosed |
| Segment target | Segment Regenerative medicine products business / Sales Target ¥3.5 billion / Profit Target Not disclosed / Timing FY2027, Segment Regenerative medicine contract services business / Sales Target ¥1 billion / Profit Target Not disclosed / Timing FY2027, Segment Labsite business / Sales Target ¥500 million / Profit Target Not disclosed / Timing FY2027 |
| Non-financial targets | Indicator Jack cases / Target value 350 cases/year / Timing Fiscal 2026, Indicator Jack cases / Target value 600 cases/year / Timing FY2027, Indicator Jasmine cases / Target value 50 cases/year / Timing Fiscal 2026, Indicator Jasmine cases / Target value 100 cases/year / Timing FY2027, Indicator Establishing a framework for commercial manufacturing (CMO) / Target value 3 items / Timing FY2027, Indicator Regular Labsite customers / Target value 8 companies / Timing FY2025, Indicator Regular Labsite customers / Target value 11 companies / Timing Fiscal 2026, Indicator Completion of German subsidiary establishment / Target value First half of the fiscal year ending March 2027 / Timing Fiscal year ending March 2027, Indicator Launch of intestinal epithelial model / Target value Second half of the fiscal year ending March 2027 / Timing Fiscal year ending March 2027 |
| Plan assumptions | Maintain recovery at Q4 FY2026 levels, Cost control at a 10% profit margin |
| Key initiatives | Evolve into an active, specialized division structure by business area, Double Jack revenue, Develop the market for Jasmine, Build a stable earnings base through phase advancement, Deliver unique value as an innovation partner, Create synergies with Teijin, Accelerate European expansion and establish manufacturing facilities, Enter new industries, Further strengthen the platform, Develop new exit strategies, Realize new technologies, Upgrade collaboration and production capabilities |
| Reason for revision or withdrawal | Allo-JaCE03 was delayed by 1 year due to the extension of the implementation period for establishing a stable manufacturing process, The launch timing for the intestinal model was reset to the second half of the fiscal year ending March 2027, with priority given to establishing an appropriate quality evaluation system |
| Size of the Target Market | Region EU / Market Size ¥16 billion / CAGR 3.8％ / Source MARKETSANDMARKETS「IN VITRO TOXICITY TESTING MARKET GLOBAL FORECAST TO 2025」, Region United States / Market Size ¥17.4 billion / CAGR 7.1％ / Source MARKETSANDMARKETS「IN VITRO TOXICITY TESTING MARKET GLOBAL FORECAST TO 2025」, Region India / Market Size ¥4.7 billion / CAGR 12.5％ / Source MARKETSANDMARKETS「IN VITRO TOXICITY TESTING MARKET GLOBAL FORECAST TO 2025」, Market Global non-genetically modified cell therapy / Market Size 875 (total pipeline) / Growth rate Up 6% from December 2022 / Source American Society of Gene & Cell Therapy / Citeline「Gene, Cell, & RNA Therapy Landscape」 |
| Risks identified | Changes in the market environment (lower sales due to market size and competitive conditions, and contract revisions resulting from policy changes by contracting parties), Stable product supply and procurement (difficulty procuring hard-to-substitute raw materials and manufacturing stoppages), Changes in laws and regulations (unexpected legal amendments and changes in healthcare administration), Loss of specialized personnel (employee turnover amid intensifying competition and the spread of diverse work styles), Large-scale disasters (operational shutdowns due to concentration of facilities and surgical delays caused by pressure on medical services), Information leaks (leakage of confidential information due to cyberattacks or employee negligence) |
| Publication date | 1 May 2026 |
Items this document does not state (10)
Net income targetROE targetROIC targetPayout ratio / DOE policyTreasury share acquisition policyCost of capitalSelf-assessment of PBR and share priceTotal investment planResults under the previous planDate of board resolution
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The FY2027 targets remain unchanged. The company established clear milestones for each business toward achieving them. It also explained that the launch timing was reset because the implementation period for establishing a stable manufacturing process for Allo-JaCE03 was extended, while priority was given to establishing an appropriate quality evaluation system for the intestinal model.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.